Canaccord Genuity Group Reaffirms Buy Rating for Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics (NASDAQ:VYGR)‘s stock had its “buy” rating restated by equities researchers at Canaccord Genuity Group in a research note issued to investors on Thursday,Benzinga reports. They currently have a $14.00 price target on the stock. Canaccord Genuity Group’s price target would suggest a potential upside of 148.23% from the company’s previous close.

A number of other equities research analysts also recently commented on VYGR. Leerink Partners assumed coverage on Voyager Therapeutics in a report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 target price for the company. StockNews.com downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Sunday, November 10th. Wedbush lowered their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research note on Thursday. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Voyager Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $17.00.

Voyager Therapeutics Trading Down 9.3 %

NASDAQ:VYGR opened at $5.64 on Thursday. The company has a market capitalization of $308.11 million, a P/E ratio of 7.94 and a beta of 0.89. Voyager Therapeutics has a 12 month low of $5.59 and a 12 month high of $11.72. The firm has a fifty day simple moving average of $6.62 and a 200-day simple moving average of $7.50.

Insider Activity

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the sale, the insider now directly owns 86,001 shares in the company, valued at approximately $500,525.82. The trade was a 6.52 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Barclays PLC raised its stake in Voyager Therapeutics by 55.8% in the 3rd quarter. Barclays PLC now owns 104,462 shares of the company’s stock valued at $612,000 after purchasing an additional 37,398 shares during the last quarter. Erste Asset Management GmbH purchased a new stake in shares of Voyager Therapeutics during the third quarter worth $6,192,000. Verition Fund Management LLC acquired a new stake in shares of Voyager Therapeutics in the third quarter valued at about $216,000. BNP Paribas Financial Markets lifted its stake in shares of Voyager Therapeutics by 30.5% in the third quarter. BNP Paribas Financial Markets now owns 49,235 shares of the company’s stock worth $288,000 after buying an additional 11,516 shares in the last quarter. Finally, FMR LLC lifted its stake in Voyager Therapeutics by 26.9% in the 3rd quarter. FMR LLC now owns 92,498 shares of the company’s stock worth $541,000 after purchasing an additional 19,622 shares in the last quarter. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.